(via a tweet by JAMAPsychiatry)
# Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity (published 3 September 2025)
Key points:
Question Can the glucagon-like peptide-1 receptor agonist semaglutide safely reduce glucose levels and body weight in patients with schizophrenia, prediabetes, and obesity?
Findings In this placebo-controlled randomized clinical trial of 154 patients with schizophrenia, overweight or obesity, and prediabetes, 30 weeks of semaglutide, 1.0 mg/week, significantly lowered glycosylated hemoglobin A1c. Moreover, semaglutide reduced body weight by a mean value of 9.21 kg and improved physical quality of life without exerting negative mental health consequences.
Meaning Semaglutide is safe and effective for lowering blood glucose and weight in patients with schizophrenia who also experience overweight or obesity and prediabetes.